Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Spinoff of the lab worth?
View:
Post by Fruckedagain on Apr 21, 2024 8:38am

Spinoff of the lab worth?

I'm thinking the experts in the market are looking at the value of the lab as being worth at least $1 million and maybe you can addd 12% interest on the value. At least enough value to payout debt I would think.
Comment by forhandlaren on Apr 21, 2024 2:43pm
Quite impressive how many posts without any valuable content one can produce so frequently!
Comment by Fruckedagain on Apr 21, 2024 4:07pm
You can almost...well you can...say that about the content of Howhee's updates and NRs. The market experts are punishing the SBM crew for they way they conduct business. We would be north of $1.00 if there was any cedibility in what we are lead to believe is happening. Don't you ask yourself what the market is seeing that you are too blind or to stupid to want to know?
Comment by tylerreddick on Apr 21, 2024 4:22pm
Not sure who posted the original post in the thread, but spinning off the part of the company that has the only potential money-maker wouldn't be something I would vote for. AbbVie remains a complete unknown.
Comment by lscfa on Apr 21, 2024 5:19pm
Agreed. 1326 is the big potential ingredient. 1067, so far, has only been formulated into a margin product by R+F and Abbvie's 1st product might be the same thing, a dark spot corrector.
Comment by PeterG on Apr 22, 2024 5:33am
Agree. The question remains open where the money is coming for the launch in Q1 2025. I'm pretty sure that Howard can't invest further Millions, the trust is gone into the company for a while. So I'm really nervous. Further dilution might come, however, the last PP has already shown less interest. I also can't see an Allergan launch in 2024 as there are no clicial trials showing on ...more  
Comment by tylerreddick on Apr 22, 2024 8:39am
SBM already said they are looking for a money partner for Sirona labs, which will obviously mean we get less of the pie. But a smaller part of the pie is better than no pie at all. Get with the program.
Comment by forhandlaren on Apr 22, 2024 3:24pm
The anti-aging clinical trial results were solid, well documented and impressive. It will not be hard to find a financial partner, the risk reward is very attractive. Yes, some profit will be directed to the partner - but - most likely much better deal anyway for the shareholders compared to a licensing deal. How big part will the financial partner get? It basically depends on two factors ...more  
Comment by tylerreddick on Apr 22, 2024 5:23pm
Throwing dung at the wall again? You are just guessing. Sirona Labs will have to be very close to a partner deal if they are going to meet their schedule, that is all we know for sure.
Comment by Fruckedagain on Apr 22, 2024 5:42pm
Redick (AKA Howie's buddie). Accoring to the last efforst to raise money, and where the CEO is not leading us astray, There is no money. He can't raise enough money to provide the lab with a stock of toilette paper for gawds sake. Question..what has the CSO really reated in 16 years that has tuened into a cash commercil produt...to help pay for toillete paper? I think that is a good ...more  
Comment by lscfa on May 06, 2024 8:12am
Sirona Labs could be financed like ASEP did. It created a JV with a co. who contributed $7M in cash for 75% of the JV. ASEP contributed the IP for 25%. Also, the JV pays a 5% royalty to ASEP on future sales.     
Comment by SleepyHoward on May 06, 2024 9:27am
Where are these numbers from?
Comment by Fruckedagain on May 06, 2024 4:03pm
This post has been removed in accordance with Community Policy
Comment by MirrorWorldMan on Apr 22, 2024 11:50am
Owners need to know why there is a delay launching 1067, potential revenue timelines or if the contract with AbbVie is cancelled. With no information, they value of the deal is considered to be zero and this 6.5 cent share price is all there is.  
Comment by Pareto8020 on Apr 22, 2024 3:10pm
Yes Howard should of requested the ability to provide some basic info versus complete lockdown of all information.  Even some super basic info would have helped buoy the shareprice knowing that royalties were streaming soon. Still mind boggling that the CEO with next to no money in the bank convinced the board - hey let's take next to nothing for an upfront and try and make our money ...more  
Comment by Pandora on Apr 21, 2024 6:48pm
Well I see Tyler Reddick was a winner on the NASCAR oval today. Can he do something to bring SBM into the winners circle?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities